Peter Verdult

Stock Analyst at Citigroup

(n/a)

# 4,549

Out of 4,843 analysts

5

Total ratings

n/a

Success rate

-28.83%

Average return

Main Sectors:

Top Industries:

Drug Manufacturers - General Drug Manufacturers - Specialty & Generic Biotechnology

Stocks Rated by Peter Verdult

	Stock	Action	Price Target	Current	Upside	Ratings	Updated
	LLY Eli Lilly and Company	Maintains: Buy	$1,250 → $1,190	$737.67	+61.32%	3	Jan 28, 2025
	EVO Evotec SE	Upgrades: Buy	n/a	$3.96	-	1	Jun 8, 2023
	GLPG Galapagos NV	Upgrades: Buy	n/a	$28.76	-	1	Jan 27, 2022

Eli Lilly and Company

Jan 28, 2025

Maintains: Buy

Price Target: $1,250 → $1,190

Current: $737.67

Upside: +61.32%

Evotec SE

Jun 8, 2023

Upgrades: Buy

Price Target: n/a

Current: $3.96

Upside: -

Galapagos NV

Jan 27, 2022

Upgrades: Buy

Price Target: n/a

Current: $28.76

Upside: -